A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior
therapies. The study will take place globally at multiple study centers. Subjects will be
enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and
will repeat this schedule until the cancer gets worse or the subject is unable to tolerate
ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how
active it is in ALK positive NSCLC.